{
      "Rank": 300,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "cAMR patients in this group receive additional intravenous allogeneic BM-MSCs (1*10^6/kg) every two weeks for four consecutive doses, besides current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.",
            "cAMR patients in this group receive current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib."
      ],
      "ArmGroupInterventionName": [
            "Other: BM-MSCs",
            "Other: Desensitization therapy (PP, IVIG, rituximab or Bortezomib)",
            "Other: Desensitization therapy (PP, IVIG, rituximab or Bortezomib)"
      ],
      "ArmGroupLabel": [
            "MSCs group",
            "Control group"
      ],
      "ArmGroupType": [
            "Experimental",
            "Active Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02563340"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This study is designed to investigate the efficacy and safety of allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) on chronic antibody-mediated rejection (cAMR) after kidney transplantation. Chronic AMR is diagnosed according to Banff criteria 2013 based on renal graft biopsy and donor specific antibodies (DSA) examination. cAMR patients are assigned to MSCs group or control group. Patients in control group are prescribed to current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib, depending on individual pathological and immunological features (eg. DSA type and titer) of each study subjects. Patients in MSCs group receive additional BM-MSCs therapy besides desensitization treatments as in control group. Allogeneic BM-MSCs (1*10^6/kg) are intravenously administered every two weeks for four consecutive doses. All cAMR patients are followed up for one year. Renal function, DSA level, pathological features, patient/graft survival, and severe adverse events are monitored during the follow-up period. Immunological features of patients in both groups are consecutively examined."
      ],
      "BriefTitle": [
            "Effect of BM-MSCs on Chronic AMR After Kidney Transplantation"
      ],
      "CentralContactEMail": [
            "wangchx@mail.sysu.edu.cn",
            "liulshan@mail.sysu.edu.cn"
      ],
      "CentralContactName": [
            "Changxi Wang, M.D., Ph.D",
            "Longshan Liu, M.D., Ph.D"
      ],
      "CentralContactPhone": [
            "86-20-87333428",
            "86-20-87306082"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "OTHER"
      ],
      "CollaboratorName": [
            "Second Affiliated Hospital of Guangzhou Medical University"
      ],
      "CompletionDate": [
            "November 2017"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Kidney Transplantation"
      ],
      "ConditionAncestorId": [],
      "ConditionAncestorTerm": [],
      "ConditionBrowseBranchAbbrev": [
            "Rare",
            "All"
      ],
      "ConditionBrowseBranchName": [
            "Rare Diseases",
            "All Conditions"
      ],
      "ConditionBrowseLeafAsFound": [],
      "ConditionBrowseLeafId": [
            "T1303",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "Chronic Graft Versus Host Disease",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "low",
            "low"
      ],
      "ConditionMeshId": [],
      "ConditionMeshTerm": [],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Non-Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Single"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nkidney transplantation\ncAMR diagnosis is determined based on renal graft biopsy and DSA examination\nPatient is willing and capable of giving written informed consent for study participation and able to participate in the study for 12 months\n\nExclusion Criteria:\n\nCombined or multi-organ transplantation\nWomen who are pregnant, intend to become pregnant in the next 1 years, breastfeeding, or have a positive pregnancy test on enrollment or prior to study medication administration\nDonors or recipients are known hepatitis C antibody-positive or polymerase chain reaction (PCR) positive for hepatitis C\nDonors or recipients are known hepatitis B surface antigen-positive or PCR positive for hepatitis B\nDonors or recipients are known human immunodeficiency virus (HIV) infection\nPatients with active infection\nRecipients with a history of substance abuse (drugs or alcohol) within the past 6 months, or psychotic disorders that are not capable with adequate study follow- up\nPatients with severe cardiovascular dysfunction\nWBC<3*10^9/L or RBC <5g/dL\nHighly allergic constitution or having severe history of allergies\nPatients with active peptic ulcer disease, chronic diarrhea, or gastrointestinal problem affect absorption\nPatients with a history of cancer within the last 5 years\nPrisoner or patients compulsorily detained (involuntarily incarcerated) for treatment or either a psychiatric or physical (e.g. infectious disease) illness\nRenal graft function deteriorates due to non-immunological complication, such as surgical issues or drug nephrotoxicity"
      ],
      "EnrollmentCount": [
            "60"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000074322",
            "D000000970",
            "D000007155",
            "D000045505",
            "D000018501"
      ],
      "InterventionAncestorTerm": [
            "Antineoplastic Agents, Immunological",
            "Antineoplastic Agents",
            "Immunologic Factors",
            "Physiological Effects of Drugs",
            "Antirheumatic Agents"
      ],
      "InterventionArmGroupLabel": [
            "MSCs group",
            "Control group",
            "MSCs group"
      ],
      "InterventionBrowseBranchAbbrev": [
            "ANeo",
            "All",
            "ARhu"
      ],
      "InterventionBrowseBranchName": [
            "Antineoplastic Agents",
            "All Drugs and Chemicals",
            "Antirheumatic Agents"
      ],
      "InterventionBrowseLeafAsFound": [
            "Peripheral",
            "Two"
      ],
      "InterventionBrowseLeafId": [
            "M376",
            "M9336",
            "M3377",
            "M373",
            "M18269",
            "M7988",
            "M19343",
            "M1346",
            "M9353",
            "M19757"
      ],
      "InterventionBrowseLeafName": [
            "Bortezomib",
            "Immunoglobulins",
            "Antibodies",
            "Rituximab",
            "Immunoglobulins, Intravenous",
            "gamma-Globulins",
            "Rho(D) Immune Globulin",
            "Antineoplastic Agents, Immunological",
            "Immunologic Factors",
            "Antirheumatic Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.",
            "At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition."
      ],
      "InterventionMeshId": [
            "D000069283",
            "D000069286"
      ],
      "InterventionMeshTerm": [
            "Rituximab",
            "Bortezomib"
      ],
      "InterventionName": [
            "BM-MSCs",
            "Desensitization therapy (PP, IVIG, rituximab or Bortezomib)"
      ],
      "InterventionOtherName": [
            "allogeneic bone marrow-derived MSCs"
      ],
      "InterventionType": [
            "Other",
            "Other"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "kidney transplantation",
            "antibody-mediated rejection",
            "mesenchymal stem cell therapy",
            "donor specific antibody",
            "acute rejection"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Not yet recruiting"
      ],
      "LastUpdatePostDate": [
            "September 30, 2015"
      ],
      "LastUpdatePostDateType": [
            "Estimate"
      ],
      "LastUpdateSubmitDate": [
            "September 28, 2015"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "First Affiliated Hospital, Sun Yat-Sen University"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Guangzhou"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "The First Affiliated Hospital, Sun Yat-sen University"
      ],
      "LocationState": [
            "Guangdong"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "510080"
      ],
      "MaximumAge": [
            "65 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Efficacy and Safety of Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) on Chronic Antibody-mediated Rejection (cAMR) After Kidney Transplantation: A Multi-center Perspective Study"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "First Affiliated Hospital, Sun Yat-Sen University"
      ],
      "OrgStudyId": [
            "MSC-KTx-cAMR-150926"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "First Affiliated Hospital, Sun Yat-Sen University"
      ],
      "OverallOfficialName": [
            "Changxi Wang, M.D., Ph.D"
      ],
      "OverallOfficialRole": [
            "Study Chair"
      ],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "October 2017"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "eGFR at month 12 after enrollment"
      ],
      "PrimaryOutcomeMeasure": [
            "Estimated glomerular filtration rate (eGFR)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 months"
      ],
      "ReferenceCitation": [
            "Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W, Li X, Chen Z, Ma J, Liao D, Li G, Fang J, Pan G, Xiang AP. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation. 2013 Jan 15;95(1):161-8. doi: 10.1097/TP.0b013e3182754c53. Erratum in: Transplantation. 2014 Mar 27;97(6):e37. Pan, Guanghui [added]."
      ],
      "ReferencePMID": [
            "23263506"
      ],
      "ReferenceType": [
            "background"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "First Affiliated Hospital, Sun Yat-Sen University"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Changxi Wang"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Director of Organ Transplant Center"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "patient survival rate at month 12 after enrollment",
            "graft survival rate at month 12 after enrollment",
            "Change of DSA level up to 12 months after enrollment",
            "Change of pathological scores according to Banff 2013 criteria"
      ],
      "SecondaryOutcomeMeasure": [
            "Patient survival rate",
            "Graft survival rate",
            "Donor specific antibody (DSA) level",
            "Pathological manifestation",
            "Severe adverse events"
      ],
      "SecondaryOutcomeTimeFrame": [
            "12 months",
            "12 months",
            "12 months",
            "12 months",
            "12 months"
      ],
      "SeeAlsoLinkLabel": [
            "Previous publication"
      ],
      "SeeAlsoLinkURL": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23263506"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "November 2015"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "September 2015"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "September 30, 2015"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "September 26, 2015"
      ],
      "StudyFirstSubmitQCDate": [
            "September 28, 2015"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}